TranXenoGen, Inc had been one of the few a publicly traded US companies listed on the Alternative Investment Market of the London Stock Exchange (TXN.L). The Company had focused on developing new methods for manufacturing therapeutic proteins and a portfolio of products. Its product pipeline included Anti-Neoplastic Urinary Protein ("ANUP") for the treatment of several types of cancer, Insulin and Human Serum Albumin ("HSA"). From the assumption that the firm's technology platform would have multiple applications work includes the generation of transgenic chickens for the manufacture of high volume therapeutic proteins, animal models for the study of disease, and high throughput production of antibodies from genomic derived targets for product identification. TranXenoGen is developing its technology platform for the production of generic biologicals (e.g., Insulin and HSA), contract manufacturing of third party products and potential applications in the areas of biodefense and vaccine development. Website continues to load (Sept 2015) but withno data after 2005.
